|Bid||0.0000 x 1000|
|Ask||1.8400 x 900|
|Day's Range||1.4600 - 1.5400|
|52 Week Range||1.0320 - 6.9000|
|Beta (3Y Monthly)||-0.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.95|
On a per-share basis, the San Francisco-based company said it had a loss of 34 cents. The specialty pharmaceutical company posted revenue of $945,000 in the period. In the final minutes of trading on Wednesday, ...
SOUTH SAN FRANCISCO, Calif. , May 15, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the first quarter ended March 31, 2019 and provided an update ...
Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients' insurance billing and payment processes, and ships to the healthcare provider as prescribed. This system is designed to facilitate patient access to treatment by streamlining the product ordering and fulfillment process for healthcare providers and their staff. In February 2019, Titan announced a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime.
SOUTH SAN FRANCISCO, Calif. , May 8, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its first quarter 2019 financial results after market close on Wednesday, May 15, 2019 ...
SOUTH SAN FRANCISCO, Calif., April 29, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the granting of a marketing authorization for the medicinal product Sixmo, the brand name for Probuphine (buprenorphine) implant in the European Union ("EU"). Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
Knight Therapeutics Inc. (GUD.TO) ("Knight"), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE™, a new treatment in the fight against opioid addiction, is now being implanted in patients across the country. Approved by Health Canada in April 2018, PROBUPHINE™ is the only subdermal implant designed to deliver buprenorphine continuously for 6 months following a single treatment.
Titan Pharmaceuticals, Inc. (TTNP) reported full year 2018 results in an April 1st press release and in a subsequently filed 10-K. During the year, Titan recorded total revenues of $6.6 million compared to $0.2 million in 2017. Highlights for 2018 include the return of the Probuphine license from Braeburn, an asset purchase and license agreement with Molteni for Eurasiafrica2, the approval and launch of Probuphine in Canada by Knight and the launch of the internal sales strategy for Probuphine.
In the news release, TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, issued earlier today, April 1, 2019, by Titan Pharmaceuticals, Inc. over PRNewswire, we are advised by the company that the weighted average shares for the three months and full year ended December 31, 2019 were inadvertently reversed. SOUTH SAN FRANCISCO, Calif., April 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on its business.
On a per-share basis, the San Francisco-based company said it had a loss of 62 cents. The specialty pharmaceutical company posted revenue of $1.2 million in the period. In the final minutes of trading ...
SOUTH SAN FRANCISCO, Calif., April 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on its business. In March 2018, Titan entered into a definitive asset purchase, supply and support agreement with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. ("Molteni") where Molteni acquired the European intellectual property related to Probuphine® (buprenorphine) implant and the exclusive right to commercialize Probuphine in Europe, as well as certain other countries.
"We believe AppianRx's comprehensive patient support services utilizing its patent pending technology platform, Cassia, will help optimize patient care by facilitating more efficient interactions among physicians, payors and specialty pharmacies," said Titan's Chief Commercial Officer, Dane Hallberg.
Management Team to Host Conference Call on April 2, 2019 at 8:30 a.m. ET / 5:30 a.m. PT SOUTH SAN FRANCISCO, Calif. , March 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced ...
CORAL GABLES, FL / ACCESSWIRE / February 25, 2019 / The future success of the healthcare stock market will be determined by whether companies in the industry are aptly prepared to meet the growing demands for better healthcare. Medical professionals are now advocating for legislation in favor of legalizing marijuana because of the list of health benefits afforded to those who use medicinal cannabis. TSX: ACB), and Actinium Pharmaceuticals Inc (NYSE American: ATNM) represent four healthcare companies focused on improving the quality of life for their patients.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced the execution of a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, Titan's unique six-month maintenance treatment for opioid use disorder (OUD) in eligible patients. Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy such as AllianceRx Walgreens Prime carries inventory, directly handles the subsequent patients' insurance billing and payment processes, and ships to the health care provider as prescribed.
We have now had more than two full quarters of in-house management of Probuphine commercialization by Titan Pharmaceuticals, Inc. (TTNP) and indications are that shipment trends are strong. Since the company had their licenses returned in late May 2018 Titan has implemented a new strategy to grow sales for the innovative implant Probuphine, which is intended for maintenance treatment in patients that are stable on a transmucosal buprenorphine product. In a release last week the company highlighted a 20% sequential increase in shipments in the second half of the year.
With the advent of new approaches to medical care, as well as innovative medical technologies coming out of the healthcare industry, news surrounding innovative companies putting their skills to the test in the has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aileron Therapeutics Inc (ALRN), Enochian Biosciences Inc (ENOB) represent four healthcare stocks setting the pace on Friday afternoon. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
Why Titan Pharmaceuticals Is Soaring TodayStock price movementsOn January 31, 2019, Titan Pharmaceuticals (TTNP) issued a press release announcing a 20% rise in shipments of its Probuphine implant used to treat opioid use disorder. The positive
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. We often see insiders buying up shares in Read More...
Titan Pharmaceuticals stock was soaring Friday on news concerning the relaunch of Probuphine. Source: Titan Pharmaceuticals Titan Pharmaceuticals' (NASDAQ:TTNP) Probuphine is a subdermal implant that delivers buprenorphine to a patient. This implant only requires a single procedure to be put in place and works for six months. Titan Pharmaceuticals notes that Probuphine is used to treat adults that are suffering from opiod addiction. This includes addition from both prescription and illegal versions of the drug. It got approval from the U.S. Food and Drug Administration in May 2016 and is the only implant of its kind for treating this type of addiction. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The good news for Titan Pharmaceuticals is that a recent relaunch of Probuphine is performing well. The company says that it has seen a double digit increase in shipments of the device during the period of its relaunch, which was in mid-June 2018. Titan Pharmaceuticals stock is also getting a boost from the company saying that shipments of Probuphine have continued to increase 20% sequentially for the rest of 2018. It will provide more details about this when it releases its earnings report for the fourth quarter of 2018 in March. * 7 S&P 500 Stocks to Buy That Tore Up Earnings The news release that has Titan Pharmaceuticals stock on the move today also includes other details about the Probuphine relaunch. Among these are it acquiring commercial and medical affairs personnel for all targeted regions to help the treatment grow. It also has a government relations firm that is helping with a lobbying plan for Probuphine. TTNP stock was up 33% as of Friday morning. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post Why Titan Pharmaceuticals Stock Is Skyrocketing Today appeared first on InvestorPlace.
NEW YORK, NY / ACCESSWIRE / February 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), today provided an update on the U.S. commercial relaunch of Probuphine (buprenorphine) implant, its unique six-month treatment for Opioid Use Disorder (OUD). Titan also reengaged with health care providers who had previously treated patients with Probuphine, providing retraining and medical liaison assistance where needed and creating an integrated sales strategy to support them and their office staff. Based on preliminary information, total shipments of Probuphine during the rest of the year increased sequentially by over 20%. Titan expects to provide more details in its fourth quarter and full-year 2018 financial results, which it expects to release in late March 2019.
SOUTH SAN FRANCISCO, Calif. , Jan. 24, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a commercial stage company developing proprietary therapeutics using its ProNeura™ long-term continuous ...